csirt@kutim:~/threat-intel/cve/CVE-2025-8311

Katalog CVE

CVSS 9.4 · Critical EPSS 1,7%

Kerentanan Improper Neutralization of Special Elements used in an SQL Command ('SQL Injection'). Skor CVSS 4.0 9.4 (Critical) menurut dotcms.com.

Deskripsi (NVD)

dotCMS versions 24.03.22 and after, identified a Boolean-based blind SQLi vulnerability in the /api/v1/contenttype endpoint. This endpoint uses the sites query parameter, which accepts a comma-separated list of site identifiers or keys. The vulnerability was triggered via the sites parameter, which was directly concatenated into a SQL query without proper sanitization. Exploitation allowed an authenticated attacker with low privileges to extract data from database, perform privilege escalation, or trigger denial-of-service conditions. The vulnerability was verified using tools such as SQLMap and confirmed to allow full database exfiltration and potential denial-of-service conditions via crafted payloads. The vulnerability is fixed in the following versions of dotCMS stack: 25.08.14 / 25.07.10-1v2 LTS / 24.12.27v10 LTS / 24.04.24v21 LTS

Rincian

Terbit di NVD
4 September 2025
Terakhir diubah
17 Juni 2026
Status NVD
Deferred
CVSS 4.0
9.4 (Critical), sumber dotcms.com
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-89: Improper Neutralization of Special Elements used in an SQL Command ('SQL Injection')
EPSS (30 hari)
1,7% peluang dieksploitasi; lebih tinggi dari 76,7% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.